不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
比较 lisocabtagene maraleucel 与外部对照臂在三线或更后线复发/难治性滤泡性淋巴瘤中的结局
英文原题：Comparative outcomes of lisocabtagene maraleucel versus an external control arm in third-line or later relapsed or refractory follicular lymphoma.
查看英文原题
Comparative outcomes of lisocabtagene maraleucel versus an external control arm in third-line or later relapsed or refractory follicular lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
在TRANSCEND FL研究中，lisocabtagene maraleucel（liso-cel）展现出强效疗效，在三线或更晚（3 L+）滤泡性淋巴瘤（FL）患者中，总缓解率（ORR）达97%，完全缓解（CR）率达94%。
在此，我们通过构建一个来自历史临床试验和真实世界实践的患者外部对照臂（ECA），将TRANSCEND FL中liso-cel的疗效和安全性与此标准治疗（SOC[排除T细胞衔接疗法]）进行比较。使用逆概率治疗加权（IPTW），使ECA队列与TRANSCEND FL保持均衡匹配。经过IPTW后，接受liso-cel治疗的患者ORR（相对风险：1.4；95%置信区间[CI]：1.3-1.6）和CR率（2.4；2.1-2.7）显著高于SOC。缓解持续时间（0.26；0.15-0.46）、至下次治疗时间（0.24；0.13-0.44）、无进展生存期（0.28；0.17-0.48）和总生存期（0.40；0.19-0.84）的校正风险比（95% CI）均显著有利于liso-cel，表明liso-cel相较SOC具有有意义的疗效改善，巩固了liso-cel作为3 L+ FL患者治疗选择的地位。
展开英文摘要原文
In TRANSCEND FL, lisocabtagene maraleucel (liso-cel) demonstrated strong efficacy, with 97% overall response rate (ORR) and 94% complete response (CR) rate in third-line or later (3 L+) follicular lymphoma (FL).
Here, we compared efficacy and safety of liso-cel from TRANSCEND FL to standard-of-care (SOC [excluding T-cell-engaging therapies]) by constructing an external control arm (ECA) of patients from historical clinical trials and real-world practice. Using inverse probability of treatment weighting (IPTW), ECA cohort was balanced to match TRANSCEND FL. After IPTW, liso-cel-treated patients had significantly higher ORR (relative risk: 1.
4; 95% confidence interval [CI]: 1. 3-1. 6) and CR rate (2. 4; 2. 1-2. 7) than SOC. Adjusted hazard ratios (95% CI) for duration of response (0. 26; 0. 15-0. 46), time to next treatment (0. 24; 0. 13-0. 44), progression-free survival (0. 28; 0. 17-0. 48), and overall survival (0. 40; 0. 19-0. 84) significantly favored liso-cel, demonstrating meaningful efficacy improvement with liso-cel over SOC, solidifying liso-cel as a treatment option for patients with 3 L + FL.
论文信息
- 作者
- Nastoupil LJ、Martín García-Sancho A、Izutsu K、Cartron G、Zausner Skarbnik AP、Reguera Ortega JL、Goto H、Borchmann P
- 第一作者单位
- Southwest Oncology, CommonSpirit Mercy, Durango, CO, USA.United States
- 通讯作者单位
- Memorial Sloan Kettering Cancer Center, New York, NY, USA.United States
- 文献类型
- 对照研究
- 期刊
- Leukemia & lymphoma2026 Jun
- 原文标识
- PubMed 42050853 · DOI 10.1080/10428194.2026.2650672